The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice
Abstract
Background Previous studies have demonstrated that human monoclonal and polyclonal anticardiolipin antibodies have thrombogenic properties in vivo. Using such a model in which these antibodies have been shown to increase both the size of an induced thrombus and the duration of time in which such a clot lasts, we investigated whether hydroxychloroquine alters the dynamics of such thrombus formation. Methods and Results Three groups of nine mice were injected with purified immunoglobulin G (IgG) from a patient with the antiphospholipid syndrome (IgG-APS) and then fed with hydroxychloroquine at various doses (100, 6, and 3 mg/kg body wt). Three control groups of mice were also studied, including mice injected with IgG-APS and then fed with placebo, as well as two other groups injected with IgG from normal human serum and fed either hydroxychloroquine or placebo. A standardized thrombogenic injury was subsequently induced in the femoral vein of each mouse and the area (size) of thrombus measured as well as the total period of time that thrombus was present. Mice treated with hydroxychloroquine and IgG-APS showed significantly smaller thrombi that persisted for a shorter period of time compared with animals treated with IgG-APS and placebo. Conclusions Hydroxychloroquine significantly diminished both thrombus size and total time of thrombus formation in mice previously injected with IgG-APS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Experimental studies have shown that HCQ interferes with the binding of aPL–β2-glycoprotein I complexes to phospholipid surfaces, reverses aPL-induced thrombogenicity, reduces platelet activation, downregulates endothelial tissue factor expression, modulates complement activation and improves endothelial function [3–5].”
From Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis (2026) · cites this paper as [5]
In the citing paper
“In addition, HCQ reduces platelet activation, downregulates endothelial tissue factor expression, modulates complement activation and improves endothelial function, collectively targeting multiple thrombo-inflammatory pathways central to APS pathophysiology [3, 5].”
From Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis (2026) · cites this paper as [5]
In the citing paper
“Its administration significantly reduced thrombus size and duration [8].”
From Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients (2013) · cites this paper as [8]
Citations
Cites
Handbook of Experimental Immunology.
Denman, A. (1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-6-1376_1 · Cited by 2,414
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700
Harris, E. N. (1987) · Lara D. Veeken · doi:10.1093/rheumatology/26.5.324 · Cited by 404
Self-citationBillah, M. M., Lapetina, E. G., & Cuatrecasas, P. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69214-8 · Cited by 369
Derksen, R. H. W. M., de Groot, P. G., Kater, L., & Nieuwenhuis, H. K. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.9.689 · Cited by 240
Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes.
Khamashta, M. A., Harris, E. N., Gharavi, A. E., Derue, G., Gil, A., Vázquez, J. J., & Hughes, G. R. V. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.10.849 · Cited by 226
Self-citationPierangeli, S. S., Liu, X. W., Barker, J. H., Anderson, G., & Harris, E. N. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649940 · Cited by 223
Self-citationHarris, E. N. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb02530.x · Cited by 222
Self-citationPulmonary Embolism and its Prophylaxis Following the Charnley Total Hip Replacement
JOHNSON, R., Green, J. R., & Charnley, J. (1977) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-197709000-00015 · Cited by 179
Research works printed but not linked: 4
- Knisely M, Bloch E. Microscopic observations of intravascular agglutination of red cells and consequent sludging of blood in human diseases. Anat Rec.. 1942;82:426.
- 10.1161/circ.94.7.1746 · DOI
- Cecchi E, Ferraris D. Desludging action of hydroxychloroquine in rheumatoid arthritis. Acta Med Scand.. 1962;8:214-221.
- Bird H, Harkness J, Wright V. Some rheological properties of blood during antirheumatoid therapy. Pharmatherapeutica.. 1981;3:36-39.
Cited by
Sorted by citations
Items 201–249 of 249
Silva, L. M. T., Cortes, A., Rossi, B., Boll, L. F. C., Waclawovsky, G., Eibel, B., Gonçalves, S. C., Irigoyen, M. C., & Martinez, D. (2021) · Trials · doi:10.1186/s13063-021-05610-0 · Cited by 2
antipalúdicos en el tratamiento de las enfermedades autoinmunes sistémicas y reumáticas
Sabio, J. M., & Jiménez-Alonso, J. F. (2003) · Medicina integral: Medicina preventiva y asistencial en atención primaria de la salud · Cited by 2
Syndrome des antiphospholipides : pourquoi faut-il y penser et comment faire le diagnostic ?
Sibilia, J. (2003) · Revue du Rhumatisme · doi:10.1016/s1169-8330(03)00057-7 · Cited by 2
Systemic Lupus Erythematosus and the Antiphospholipid Syndrome
Porter, T. F., & Branch, D. W. (2004) · Wiley eBooks · doi:10.1002/9780470760086.ch35 · Cited by 2
Antiphospholipid antibody syndrome (Hughes' syndrome)
Francès, C., & Pietté, J. C. (2001) · Dermatologic Therapy · doi:10.1046/j.1529-8019.2001.014002117.x · Cited by 2
Siddique, F., Patel, D. P., & Roberts, W. N. (2015) · Encyclopedia of Inflammatory Diseases · doi:10.1007/978-3-0348-0620-6_161-6 · Cited by 2
Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Abdelwahab, M., Kiefer, M. K., & Costantine, M. M. (2024) · Wiley eBooks · doi:10.1002/9781119820260.ch50 · Cited by 2
Antiphospholipid syndrome and recurrent pregnancy losses
Erra, R., Trespìdi, L., Ossola, W., & Luigi, M. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90805-4.00008-0 · Cited by 1
Han, D.-L., Li, L., Shi, J., Ge, Y., Yang, S.-L., Chu, Y., Mai, Z.-Y., Zhang, Y. L., Chen, H., Jing, Y., et al. (2026) · Trials · doi:10.1186/s13063-026-09470-4 · Cited by 1
Primary Prophylaxis in Patients With Positive Antiphospholipid Antibodies
Cuadrado, M. J. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00015-6 · Cited by 1
Chapter 80 – Treatment of Autoimmune Disease: Established Therapies
Hahn, B. H., & King, J. K. (2014) · Academic Press eBooks · Cited by 1
Clinical Aspects of Antiphospholipid Syndrome
Durcan, L., & Petri, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47927-1.00042-6 · Cited by 1
Khamashta, M. A., Pierangeli, S. S., & Harris, E. N. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00135-4 · Cited by 1
Self-citationTreatment of Autoimmune Disease
Hahn, B. H., & King, J. K. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-384929-8.00080-0 · Cited by 1
Nuevas estrategias en el tratamiento del síndrome antifosfolípido
Ibañez, S., Iruretagoyena, M., & GUTIÉRREZ-ESTRADA, M. A. (2013) · Revista médica de Chile · doi:10.4067/s0034-98872013000800011 · Cited by 1
B-Cell Targeted Therapies in Autoimmune Cytopenias and Thrombosis
Matta, B. N., Nayfe, R., Taher, A. T., & Uthman, I. W. (2013) · Milestones in drug therapy · doi:10.1007/978-3-0348-0706-7_11 · Cited by 1
A Review on Hydroxychloroquine Drug: to Combat COVID-19
(2020) · Letters in Applied NanoBioScience · doi:10.33263/lianbs94.17051716 · Cited by 1
Harnett, M. J. P., & McElrath, T. F. (2006) · Springer eBooks · doi:10.1007/0-387-21572-7_18 · Cited by 1
Dermatologic aspects of Antiphospholipid Antibody Syndrome
Francès, C., Pietté, J. C., & Asherson, R. A. (2006) · Technical report · doi:10.1016/s1571-5078(05)05009-9 · Cited by 1
Novel therapies for the antiphospholipid syndrome
Pierangeli, S. S. (2008) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.4.2.193 · Cited by 1
Self-citationRodrigues, L. D., Shinjo, S. K., Oyamada, M. K., Serracarbassa, P. D., Takahashi, W. Y., Borba, E. F., Bonfá, E., & Nakashima, Y. (2009) · Arquivos Brasileiros de Oftalmologia · doi:10.1590/s0004-27492009000300007 · Cited by 1
Dauby, N., Catteau, L., Hautekiet, J., Montourcy, M., Bottieau, E., Goetghebeur, E. J. T., & Beckhoven, D. V. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106261 · Cited by 1
Branch, D. W., & Lockshin, M. (2005) · Technical report · doi:10.1016/s1571-5078(05)04006-7 · Cited by 1
de Carvalho, J. F., Hautz, E., & Cervera, R. (2026) · Rheumatology and Therapy · doi:10.1007/s40744-026-00858-x · Cited by 3
“…shown that HCQ interferes with the binding of aPL– β 2-glycoprotein I complexes to phospholipid surfaces, reverses aPL-induced thrombo-genicity, reduces platelet activation, down-regulates endothelial tissue factor expression, modulates complement activation and improves endothelial function [3–5].”
Blank, M., Sherer, Y., & Shoenfeld, Y. (2002) · Elsevier eBooks · doi:10.1016/b978-044450987-1/50038-3
Molecular Pathogenesis of the Antiphospholipid Syndrome: Toward Novel Therapeutic Targets
Pierangeli, S. S., Vega-Ostertag, M. E., Gharavi, A. E., & Harris, E. N. (2006) · Springer eBooks · doi:10.1007/0-387-24534-0_26
Self-citationChapter 18 Difficult Clinical Situations in the Antiphospholipid Syndrome
Gordon, J., Goldenberg, D., Erkan, D., & Lockshin, M. D. (2009) · Technical report · doi:10.1016/s1571-5078(08)00418-2
Antiphospholipid Syndrome - An Evolving Story of a Multisystemic Disease
Silvia, S., Willis, R., Harper, B. E., & Manoharan, E. N. E. A. (2012) · InTech eBooks · doi:10.5772/36714
Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Porter, T. F., & Branch, D. W. (2010) · Wiley eBooks · doi:10.1002/9781444316780.ch36
Chapter 15 Treatment of Thrombosis in the Antiphospholipid Syndrome
Ruiz‐Irastorza, G., & Khamashta, M. A. (2009) · Technical report · doi:10.1016/s1571-5078(08)00415-7
Atherogenesis and Vascular Disease in SLE
Ferreira, I., & Delgado, J. (2012) · InTech eBooks · doi:10.5772/26028
Mécanismes d’activation cellulaire par les anticorps antiphospholipides
Satta, N., Kruithof, E. K. O., Reber, G., & de Moerloose, P. (2008) · Archive ouverte UNIGE (University of Geneva) · doi:10.1684/hma.2008.0283
Ghalib, M., & Hassan, I. (2010) · Arab Journal of Nephrology and Transplantation · doi:10.4314/ajnt.v2i1.58845
‘Immunomodulatory’ approaches to the management of antiphospholipid syndrome
Willis, R., González, E. B., & Pierangeli, S. S. (2012) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.77
Self-citationNew insights into the management of antiphospholipid syndrome-related thrombosis
Puente, D., & Forastiero, R. R. (2008) · Future Rheumatology · doi:10.2217/17460816.3.1.85
The future of treatment for antiphospholipid syndrome
Willis, R., Harris, E. N., & Pierangeli, S. S. (2014) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.13.73
Self-citationPatogenia e Abordagem Terapêutica do Sindrome Antifosfolipidico na Gravidez
Ourique, C. (2010) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/y7mw-qp48
Atherosclerosis risk in antiphospholipid syndrome
Ferreira, I., das Neves, M. F., & Alves, J. D. (2011) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.51
Treatment of Pregnancy Complications in Antiphospholipid Syndrome
Nassar, A. H., Uthman, I. W., Eid, J., & Khamashta, M. A. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00018-1
Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Saoud, F., & Costantine, M. M. (2018) · Wiley eBooks · doi:10.1002/9781119129400.ch51
Antipalúdicos de síntesis en dermatología
Chasset, F., Costedoat-Chalumeau, N., & Francès, C. (2020) · EMC - Dermatología · doi:10.1016/s1761-2896(20)44054-3
A Patient's Guide to the Antiphospholipid Syndrome
Berman, J., Erkan, D., & Lockshin, M. D. (2002) · Elsevier eBooks · doi:10.1016/b978-044450987-1/50040-1
Treatment of Thrombosis in Antiphospholipid Syndrome
Ruiz‐Irastorza, G., & Khamashta, M. A. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00016-8
Chighizola, C. B., & Ubiali, T. (2014) · Rare diseases of the immune system · doi:10.1007/978-3-319-11044-8_18
Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in beagle dogs
Li, X., Feng, J., Yuan, Y., Zhang, S., Xu, Z., Xu, Q., Song, J., Li, R., Yuan, Z., & Wu, W. (2022) · Drug and Chemical Toxicology · doi:10.1080/01480545.2022.2116645
Hydroxychloroquine as a potential therapy for ANCA-associated vasculitis
Jain, S., Sangle, S. R., Kim, S., John, S., & D’Cruz, D. P. (2024) · Vessel Plus · doi:10.20517/2574-1209.2023.142
Clinical aspects of antiphospholipid syndrome
Topilow, J., & Petri, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93232-5.00051-4
Antiphospholipid Syndrome — Experimental Models: Insight into Etiology, Pathogenesis, and Treatments
Blank, M., Krause, I., & Shoenfeld, Y. (2006) · Springer eBooks · doi:10.1007/1-84628-009-5_30
Metadata
- Authors
- Edwards, M. H., Pierangeli, S., Liu, X., Barker, J. H., Anderson, G., & Harris, E. N.
- Affiliations
- University of Louisville (US)
- Venue
- Circulation
- Published
- 1997-12-16
- Volume
- 96
- Issue
- 12
- Pages
- 4380-4384
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2001976130
- Cited by
- 250
- References
- 30
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 6 · 2020: 17 · 2019: 9 · 2018: 7 · 2017: 13 · 2016: 14 · 2015: 10 · 2014: 16 · 2013: 11 · 2012: 10
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hydroxychloroquine, antiphospholipid syndrome, anticardiolipin antibodies, antiphospholipid antibodies, thrombosis, thrombus size, thrombogenicity, IgG, thromboprophylaxis
- MeSH terms
- Animals, Dose-Response Relationship, Drug, Humans, Hydroxychloroquine, Immunoglobulin G, Male, Mice, Inbred Strains, Reference Values, Thrombosis, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
